Cardinal Health

Dublin, Ohio 43017

0 studies enrolling now · 6 studies all time

What they study most

Advanced Renal Cell Carcinoma (aRCC), Melanoma, Metastatic Non-small Cell Lung Cancer, Non-squamous, Non-Small Cell Lung Cancer, Oropharyngeal Squamous Cell Carcinoma

Studies at this site

• Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab — Completed
• Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients — Completed
• Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma — Completed
• Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy — Running, not enrolling
• Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S. — Completed
• A Study to Evaluate Treatment With Nivolumab Alone and Nivolumab Combined With Ipilimumab in Children With Melanoma — Completed